US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19

Overview of attention for article published in Open Forum Infectious Diseases, December 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 18 X users

patent: 1 patent

Readers on

mendeley: 31 Mendeley

So far, Altmetric has seen 19 X posts from 18 X users, with an upper bound of 174,262 followers.

We demonstrate that favipiravir can be safely administered to hospitalized adults with COVID-19 and believe that further studies are warranted. NCT04358549 https://t.co/qSA9cojZIB

US201 試験: COVID-19 の治療のためのファビピラビルの第 2 相無作為化概念実証試験アビガン　2021/12 https://t.co/9KxRt30gvm

ウイルスクリアランスまでの日数で有効性を評価すれば、こう言った結果が出るのは今迄の研究からも想像できました。抗ウイルス剤の評価はウイルスクリアランス、症状改善までの日数なども考慮されるべきだと思いますが、いつまでも重症化率や死亡率で評価しているので、なか…

RT @minesoh: ファビピラビル（アビガン）の RCT👶小規模です。まぁ…なんというかあまり効いていなさそうなことはわかるよね。 https://t.co/5XtbZGaatH

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 15 additional X posts.